| |
Age <75 years
|
Age ≥75 years
|
p value
|
|---|
|
No. of subjects
|
252
|
191
| |
|
Age (mean, years)
|
66.9
|
80.0
| |
|
Sex (male/female)
|
231/21
|
175/16
|
n.s.
|
|
Smoking amount (mean, pack-year)
|
56.9
|
55.6
|
n.s.
|
|
Current smoker (%)
|
17.3
|
7.7
|
0.004
|
|
BMI (mean, kg/m2)
|
22.5
|
22.3
|
n.s.
|
|
VC (mean, ml)
|
3365
|
2934
|
<0.001
|
|
VC (mean, % predicted)
|
93.8
|
93.5
|
n.s.
|
|
FEV1 (mean, ml)
|
1717
|
1465
|
<0.001
|
|
FEV1 (mean, % predicted)
|
60.5
|
62.1
|
n.s.
|
|
GOLD grade (I/II/III/IV)
|
52/114/67/19
|
41/88/48/14
|
n.s.
|
|
LTOT (%)
|
10.7
|
15.9
|
n.s.
|
|
CAT (mean)
|
12.5
|
12.7
|
n.s.
|
|
SGRQ symptom (mean)
|
36.5
|
37.9
|
n.s.
|
|
SGRQ activity (mean)
|
39.7
|
47.5
|
0.001
|
|
SGRQ impact (mean)
|
18.3
|
22.3
|
0.04
|
|
SGRQ total (mean)
|
27.4
|
32.2
|
0.02
|
|
Oral corticosteroids (%)
|
3.2
|
3.6
|
n.s.
|
|
Inhaled corticosteroids (%)
|
35.0
|
32.8
|
n.s.
|
|
Long-acting β2 agonists (%)
|
42.0
|
48.8
|
n.s.
|
|
Long-acting muscarinic antagonists (%)
|
64.0
|
58.3
|
n.s.
|
-
BMI body mass index, VC vital capacity, FEV
1
forced expiratory volume in 1 s, GOLD Global Initiative for Obstructive Lung Disease, LTOT long-term oxygen therapy, CAT COPD assessment test, SGRQ St George’s Respiratory Questionnaire, n.s. not significant
